扶桑薬品工業(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証PRM | 医薬品 | 4538/E00953 | Fuso Pharmaceutical Industries, Ltd. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2018/10/26 | 日証協 | 18,000株 | +1.69% | 7,300株 | -55.64% | 14,913株 | +2.76% | 3,900株 | -23.05% |
| 2018/10/19 | 日証協 | 17,700株 | +54.67% | 16,456株 | +243.26% | 14,513株 | -17.75% | 5,068株 | +94.92% |
| 2018/10/12 | 日証協 | 11,444株 | -34.4% | 4,794株 | -77.65% | 17,645株 | -17.72% | 2,600株 | -83.65% |
| 2018/10/05 | 日証協 | 17,444株 | +50.38% | 21,450株 | -9.87% | 21,445株 | +30.68% | 15,900株 | +12.77% |
| 2018/09/28 | 日証協 | 11,600株 | +132% | 23,800株 | +100% | 16,410株 | -1.33% | 14,100株 | +98.59% |
| 2018/09/21 | 日証協 | 5,000株 | -63.24% | 11,900株 | +41.67% | 16,632株 | -34.52% | 7,100株 | +86.84% |
| 2018/09/14 | 日証協 | 13,600株 | -32.34% | 8,400株 | +2.44% | 25,400株 | +0.4% | 3,800株 | -27.95% |
| 2018/09/07 | 日証協 | 20,100株 | +15.52% | 8,200株 | +925% | 25,300株 | +2.02% | 5,274株 | +32.71% |
| 2018/08/31 | 日証協 | 17,400株 | -7.45% | 800株 | -77.14% | 24,800株 | +2.48% | 3,974株 | -26.23% |
| 2018/08/24 | 日証協 | 18,800株 | -33.8% | 3,500株 | +133.33% | 24,200株 | +6.08% | 5,387株 | +389.73% |
| 2018/08/17 | 日証協 | 28,400株 | 0% | 1,500株 | 0% | 22,813株 | -0.44% | 1,100株 | -45% |
| 2018/08/10 | 日証協 | 28,400株 | +3.27% | 1,500株 | -95.34% | 22,913株 | +3.62% | 2,000株 | +33.33% |
| 2018/08/03 | 日証協 | 27,500株 | +0.73% | 32,200株 | +54.81% | 22,113株 | +5.23% | 1,500株 | +650% |
| 2018/07/27 | 日証協 | 27,300株 | -0.36% | 20,800株 | +105.94% | 21,013株 | -7.89% | 200株 | 0% |
| 2018/07/20 | 日証協 | 27,400株 | 0% | 10,100株 | 0% | 22,813株 | 0% | 0株 | 0% |
| 2018/07/13 | 日証協 | 28,700株 | -3.04% | 1,400株 | -94.44% | 23,613株 | +3.06% | 2,300株 | +475% |
| 2018/07/06 | 日証協 | 29,600株 | -4.52% | 25,200株 | +3500% | 22,913株 | +16.83% | 400株 | -95.4% |
| 2018/06/29 | 日証協 | 31,000株 | -0.96% | 700株 | 0% | 19,613株 | -18.66% | 8,700株 | +135.14% |
| 2018/06/22 | 日証協 | 31,300株 | -1.26% | 0株 | -100% | 24,113株 | +8.07% | 3,700株 | +1133.33% |
※株式分割は考慮していませんのでご注意ください。